Novo Nordisk's Cagrilintide shows promising weight loss in REDEFINE 1 sub analysis, unveiled at EASD 2025 Pharmacally Cagrilintide Peptide for Weight Loss Appetite Control & Metabolic Support Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial The Lancet Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Novo Nordisk's CagriSema Falls Short in Head to Head Trial vs Zepbound Bryce Platt, PharmD posted on the topic LinkedIn